OCT Vibrography for Biomechanical Properties of Tissues
Launched by MASSACHUSETTS GENERAL HOSPITAL · Feb 26, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool called OCT Vibrography, which is designed to measure the mechanical properties of human tissues, like the cornea in the eye, skin, and gums. The goal is to see how well this technology works in understanding the health and condition of these tissues without needing invasive procedures.
To participate in the trial, you need to be between 18 and 75 years old and generally healthy. There are specific groups for people with healthy eyes, skin, and gums, as well as a group for those with a mild or moderate eye condition called keratoconus. Participants can expect to undergo some tests using the OCT Vibrography, which is non-invasive and safe. It's important to note that certain health conditions or previous surgeries may prevent someone from joining the study. If you think you might be eligible or are interested in learning more, please reach out!
Gender
ALL
Eligibility criteria
- Group 1:
- Inclusion criteria:
- • • Subjects with healthy eyes (age 18 - 75, N = 50)
- Exclusion criteria:
- • Subjects with history of eye diseases, and previous eye surgeries.
- • Subjects with diabetes, glaucoma family history
- • Subjects allergic to anesthetic eyedrop, especially proparacaine
- • Subjects with severe allergy
- • Subjects who have difficulty biting
- • Subjects who have recurrent corneal erosion
- Group 2:
- Inclusion criteria:
- • • Subjects with healthy skin (age 18 - 75, N = 10)
- Exclusion criteria:
- • • Subjects with open cuts/sores on the skin, skin infection, or any contagious skin condition
- Group 3:
- Inclusion criteria:
- • • Subjects with healthy gingiva (age 18 - 75, N = 10)
- Exclusion criteria:
- • • Subjects with open cuts/sores on the gingiva, gingiva infection, or any contagious gingiva condition
- Group 4:
- Inclusion criteria:
- • • Mild or moderate keratoconus subjects (age 18 - 40, N = 20)
- Exclusion criteria:
- • • Subjects with K-max above 60 diopters (Pentacam imaging) are excluded
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Seok-Hyun Yun, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials